secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2026-08-06T11:05:02+00:00
Accession:  0000886163-26-000041
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand Q2 royalty rev +32% YoY; raises 2026 adj EPS guidance; closes XOMA deal
------------------------------------------------------------------------------

- Q2 royalty rev $48.0M (+32% YoY); total rev $63.7M (+34%); GAAP EPS $2.22 (vs $0.24); adj EPS $2.37 (vs $1.60).
- 2026 adj EPS guidance raised to $9.00-$9.50 (from $8.50-$9.50); total revenue guidance unchanged at $270M-$310M.
- Completed XOMA Royalty acquisition on July 14 for $39.00/share + CVR; expected to add ~$0.50 to 2026 adj EPS and ~$1.50 to 2027 adj EPS.
- Issued $700M 0% convertible notes due 2031; repurchased 228,859 shares at ~$262/share using $60M of proceeds.
- Cash & short-term investments $1.36B at June 30, up from $733.5M at Dec 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616326000041/0000886163-26-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616326000041/lgnd-20260806.htm
  HTML page:      https://secwatch.observer/filing/0000886163-26-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer